UroGen Pharma Investor Relations Material
Latest events
Study Update
UroGen Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from UroGen Pharma Ltd
Access all reports
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers. The company utilizes its proprietary RTGel technology, a reverse-thermal hydrogel that enhances the therapeutic profiles of existing drugs by providing longer exposure to the urinary tract tissue, making local therapy more effective. The company is headquartered in Princeton, NJ, with operations in Israel, and its shares are listed on the Nasdaq.
Key slides for UroGen Pharma Ltd
Study Update
UroGen Pharma Ltd
Study Update
UroGen Pharma Ltd
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
URGN
Country
🇺🇸 United States